Relationship between quantum decoherence times and solvation dynamics in condensed phase chemical systems

A relationship between the time scales of quantum coherence loss and short-time solvent response for a solute/bath system is derived for a Gaussian wave packet approximation for the bath. Decoherence and solvent response times are shown to be directly proportional to each other, with the proportionality coefficient given by the ratio of the thermal energy fluctuations to the fluctuations in the system-bath coupling. The relationship allows the prediction of decoherence times for condensed phase chemical systems from well developed experimental methods.Comment: 10 pages, no figures, late

Blinking Molecule Tracking

Abstract We discuss a method for tracking individual molecules which globally optimizes the likelihood of the connections between molecule positions fast and with high reliability even for high spot densities and blinking molecules. Our method works with cost functions which can be freely chosen to combine costs for distances between spots in space and time and which can account for the reliability of positioning a molecule. To this end, we describe a top-down polyhedral approach to the problem of tracking many individual molecules. This immediately yields an effective implementation using standard linear programming solvers. Our method can be applied to 2D and 3D tracking.

Molecule-based photonically switched half and full adder

A single molecule logic gate using electronically excited states and ionization/fragmentation can take advantage of the differences in cross-sections for one and two photon absorption. Fault tolerant optically pumped half adder and full adder are discussed as applications. A full adder requires two separate additions, and the logic concatenation that is required to implement this is physically achieved by an intramolecular transfer along the side chain of 2-phenylethyl-N,N-dimethylamine (PENNA). Solutions of the kinetic equations for the temporal evolution of the concentration of different states in the presence of time-varying laser fields are used to illustrate the high contrast ratios that are potentially possible for such devices

The risk of allergic reaction to SARS-CoV-2 vaccines and recommended evaluation and management : a systematic review, meta-analysis, GRADE assessment, and international consensus approach

Concerns for anaphylaxis may hamper severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunization efforts. We convened a multidisciplinary group of international experts in anaphylaxis composed of allergy, infectious disease, emergency medicine, and front-line clinicians to systematically develop recommendations regarding SARS-CoV-2 vaccine immediate allergic reactions. Medline, EMBASE, Web of Science, the World Health Organizstion (WHO) global coronavirus database, and the gray literature (inception, March 19, 2021) were systematically searched. Paired reviewers independently selected studies addressing anaphylaxis after SARS-CoV-2 vaccination, polyethylene glycol (PEG) and polysorbate allergy, and accuracy of allergy testing for SARS-CoV-2 vaccine allergy. Random effects models synthesized the data to inform recommendations based on the Grading of Recommendation, Assessment, Development, and Evaluation (GRADE) approach, agreed upon using a modified Delphi panel. The incidence of SARS-CoV-2 vaccine anaphylaxis is 7.91 cases per million (n = 41,000,000 vaccinations; 95% confidence interval [95% CI] 4.02-15.59; 26 studies, moderate certainty), the incidence of 0.15 cases per million patient-years (95% CI 0.11-0.2), and the sensitivity for PEG skin testing is poor, although specificity is high (15 studies, very low certainty). We recommend vaccination over either no vaccination or performing SARS-CoV-2 vaccine/excipient screening allergy testing for individuals without history of a severe allergic reaction to the SARS-CoV-2 vaccine/excipient, and a shared decision-making paradigm in consultation with an allergy specialist for individuals with a history of a severe allergic reaction to the SARS-CoV-2 vaccine/excipient. We recommend further research to clarify SARS-CoV-2 vaccine/vaccine excipient testing utility in individuals potentially allergic to SARS-CoV2 vaccines or their excipients